Monocytic Myeloid-Derived Suppressor Cells in Multiple Myeloma: Roles of Soluble Factors, Tumor-Derived Exosomes, and Modulation by Imids and Celmods (IMS 2026) - Sep 11, 2026 - Abstract #PA-308; Pres time: Sep 25, 2026; "lenalidomide and pomalidomide reduced CCL5 and MIF in myeloma cells, downregulated CCR5 in PBMCs, and induced IRF-8. Next-generation cereblon E3 ligase modulators, especially iberdomide and mezigdomide, were more potent, suppressing M-MDSC induction at nanomolar concentrations, reducing CCL5 expression, enhancing ISG15 and other interferon-related signatures in CD33-positive myeloid cells, and modulating gene expression patterns and decreasing IL-10 and MIF in myeloma cells... This reframes MM immune escape as an active, targetable process. Targeting CCL5, MIF, IL-10, exosomal miR-106a-5p/miR-146a-5p, or downstream pathways may restore anti-myeloma immunity."
IO biomarker • Myeloid-derived suppressor cells • Hematological Malignancies • Multiple Myeloma • Oncology • Targeted Protein Degradation • CCL5 • CD14 • CD33 • CRBN • IDO1 • IL10 • IL6 • IRF8 • ISG15 • MIF • MIR106A • MIR146A • MYD88 • NDUFA2 • PD-L1 • TNFA
|
|
Junya Kuroda1; Yui Niiyama-Uchibori1; Shotaro Chinen1; Taku Tsukamoto1; Yuji Shimura1
|